Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Sadif Analytics Prime
$10.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acorda Therapeutics announces notification of ANDA filing for AMPYRA


Thursday, 26 Jun 2014 06:00am EDT 

Acorda Therapeutics Inc:Submits an Abbreviated New Drug Application (ANDA) to U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of AMPYRA(reg)(dalfampridine) Extended Release Tablets, 10 mg.Law firm of Kaye Scholer is advising Acorda on the ANDA filing. 

Company Quote

35.35
-0.23 -0.65%
9 Feb 2016